EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›NBTX

NBTX

Nanobiotix S.A.

Next earnings Sep 28, 2026 · consensus $0.55 EPS, $30.5M rev

Sell
$38.40
▲ +6.79%
$38.40▲ +748.43%
over 1Y
L $4.53H $55.07
Today+6.8%
1W+11.5%
1M+4.5%
3M+23.7%
YTD+73.5%
1Y+748.4%
OverviewValuationQualityFilings
Rating
Sell
Quality
B
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy

Mixed signals in the latest filings.

Nanobiotix S.A. shows limited reported revenue.

On these fundamentals, NBTX screens as SELL on the SEC figures.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$1.95B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
S-8Filing2026-06-08open ↗6-KPeriod ending 2026-06-052026-06-05open ↗6-KPeriod ending 2026-06-022026-06-02open ↗6-KPeriod ending 2026-06-022026-06-02open ↗6-KPeriod ending 2026-05-262026-05-26open ↗6-KPeriod ending 2026-05-262026-05-26open ↗6-KPeriod ending 2026-05-222026-05-22open ↗FWPFiling2026-05-22open ↗424B5Filing2026-05-22open ↗FWPFiling2026-05-21open ↗6-KPeriod ending 2026-05-212026-05-21open ↗6-KPeriod ending 2026-05-212026-05-21open ↗

Quality score

B
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
MomentumB
4.7952-week55.07
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is Nanobiotix S.A. (NBTX) a buy?
NBTX currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is Nanobiotix S.A.'s quality score?
NBTX scores 73.57728201493217/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001760854, latest S-8 filed 2026-06-08) · EODHD · as of 7/4/2026, 4:53:38 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Recent news

market news →
Nanobiotix (NBTX) Provides Update on Operational ProgressBullish
finance.yahoo.com· 2026-06-22
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital socialBullish
globenewswire.com· 2026-06-05
Voting Rights and Shares Capital of the CompanyBullish
globenewswire.com· 2026-06-05
Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029Bearish
nasdaq.com· 2026-06-03
Nanobiotix Provides First Quarter 2026 Operational and Financial UpdateBullish
finance.yahoo.com· 2026-06-02
Nanobiotix rejoint l'indice Euronext Tech LeadersBearish
globenewswire.com· 2026-06-02

Vs tracked universe

compare →

1195 tracked peers · median

EDGAR Score74 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2

News sentiment

EODHD · 10d
Bearish
-0.29
vs typical · 24 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.